Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study
Open Access
- 6 November 2007
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 97 (11), 1499-1504
- https://doi.org/10.1038/sj.bjc.6604074
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Phase II Trial of Intravesical Gemcitabine in Bacille Calmette-Guérin–Refractory Transitional Cell Carcinoma of the BladderJournal of Clinical Oncology, 2006
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- Phase II Study to Investigate the Ablative Efficacy of Intravesical Administration of Gemcitabine in Intermediate-Risk Superficial Bladder Cancer (SBC)European Urology, 2004
- Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical TrialsJournal of Urology, 2002
- Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer:Journal of Urology, 2002
- Phase I Trial of Intravesical Gemcitabine in Bacillus Calmette-Guérin–Refractory Transitional-Cell Carcinoma of the BladderJournal of Clinical Oncology, 2002
- 5-YEAR FOLLOWUP OF A RANDOMIZED PROSPECTIVE STUDY COMPARING MITOMYCIN C AND BACILLUS CALMETTE-GUERIN IN PATIENTS WITH SUPERFICIAL BLADDER CARCINOMAJournal of Urology, 1999
- A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinumEuropean Journal of Cancer, 1998
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989